My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc. - Common Shares (NQ:THTX)

3.320 +0.010 (+0.30%)
Streaming Delayed Price Updated: 10:25 AM EDT, Sep 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Theratechnologies Inc. - Common Shares

< Previous 1 2 3 4 Next >
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
From Theratechnologies
Via GlobeNewswire
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
From Theratechnologies
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TEGNA Inc. (NYSE - TGNA), NorthWestern Energy Group, Inc. (Nasdaq - NWE), Theratechnologies Inc. (Nasdaq - THTX), Dogwood State Bank (OTC - DSBX)
From Brodsky & Smith LLC
Via GlobeNewswire
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Second Quarter 2025
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Second Quarter 2025 Financial Results
From Theratechnologies
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Olo Inc. (NYSE - OLO), Theratechnologies Inc. (Nasdaq - THTX), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC)
From Brodsky & Smith LLC
Via GlobeNewswire
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports on its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies Provides Update on Sale Process
From Theratechnologies
Via GlobeNewswire
Soleus Capital Issues Letter to The Board of Theratechnologies
From Soleus Capital Management, L.P.
Via Business Wire
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment
Via AB Newswire
Topics Artificial Intelligence
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
From Theratechnologies
Via GlobeNewswire
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
From Theratechnologies
Via GlobeNewswire
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
Study Demonstrates Excess Visceral Abdominal Fat Drives CV Risk 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Resumes Distribution of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Theratechnologies Provides Update on EGRIFTA SV® Supply
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
From Theratechnologies
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.